The launch of phase 1 Ebola vaccine studies is a first step in developing a vaccine that could be licensed and used in the field to protect not only the front line health care workers but also those living in areas where Ebola virus exists.
Testing two vaccines against different H1N1s at the same time has never been done.
We are grateful to the Liberian people who volunteered for this important clinical trial and encouraged by the study results seen with the two investigational Ebola vaccine candidates.
